DHL Supply Chain Operations
DHL Supply Chain Operations is recorded as a service provider in 13 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 13 of 13 trials · Latest update first
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients With resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The study enrolled 451 participants at 120 investigative sites in 24 countries from 24 April 2018 to 31 December 2025.
- Because of an unexpected slowing of the EFS rate, the pre-planned second interim IRF-EFS analysis was converted to the final IRF-EFS analysis, with longer follow-up than originally planned.
These findings describe the trial, not the service provider’s performance or responsibility.
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored remibrutinib study and are judged by the investigator to benefit from continued treatment with remibrutinib
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with polymyalgia rheumatica (PMR)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The trial enrolled 381 participants across 134 investigative sites in 27 countries.
- EEA countries enrolled 199 of 381 participants; the largest EEA enrollment was in France (45), the Czech Republic (33), and Germany (27).
These findings describe the trial, not the service provider’s performance or responsibility.
A global, multicenter, randomized, double-blind, double-dummy, parallel-group, Phase 3b study to assess the efficacy, safety, and tolerability of remibrutinib 25 mg b.i.d. in comparison to placebo with omalizumab 300 mg every 4 weeks as active control over 52 weeks in adult patients with chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines and an open-label 52-week optional extension to assess long-term efficacy, safety and tolerability of remibrutinib 25 mg b.i.d.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab with or without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have not Progressed following Definitive Concurrent Chemoradiotherapy
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Randomized, Observer-Blinded Trial to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Participants ≥11 to <15 Years of Age
Sponsor GlaxoSmithKline Biologicals
- Start (EU)
- Latest update
- Estimated end
A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, an Anti- TIGIT Antibody, in Combination with Atezolizumab in Chemotherapy-Naive Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor Genentech Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Randomized, Double-Blind Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed after Concurrent Platinum-Based Chemoradiation (SKYSCRAPER-03)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase IIIb, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CMLCP) previously treated with 2 or more tyrosine kinase inhibitors
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma
Sponsor Genentech Inc.
- Start (EU)
- Latest update
- Estimated end
A double-blind, randomized, placebo-controlled trial to evaluate the efficacy, pharmacokinetics and safety of remibrutinib (LOU064) for 24 weeks in adolescents from 12 to less than 18 years of age with chronic spontaneous urticaria inadequately controlled by H1-antihistamines followed by an optional open-label extension for up to another 3 years and an optional safety long-term treatment-free follow-up period for up to an additional 3 years.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for DHL Supply Chain Operations?
The 2026-10-09 snapshot links DHL Supply Chain Operations to 13 distinct CTIS trials. Recorded services include Medicinal product management, Drug Management, Other Third Party Duty, Regional warehousing – EU hub, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for DHL Supply Chain Operations?
The most frequently recorded therapeutic areas are Allergy, Dermatology, Musculoskeletal, Respiratory. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to DHL Supply Chain Operations conducted?
The linked trials record locations in 21 countries, including Spain, Germany, France, Poland, Italy. These are trial locations, not confirmed office locations or countries where DHL Supply Chain Operations delivered services.
What can this page tell me about DHL Supply Chain Operations's trial experience?
Browse 13 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 2 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under DHL Supply Chain Operations. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- DHL Supply Chain Operations GmbH